UTAH MEDICAL PRODUCTS INC (UTMD)
Health Care · Medical Devices · NASDAQ
Utah Medical Products develops and manufactures specialized, cost-effective medical devices designed to improve patient safety and outcomes in labor, delivery, and neonatal intensive care.
What UTAH MEDICAL PRODUCTS INC does
Utah Medical Products produces medical devices focused on neonatal intensive care, labor and delivery, and women's health. The company designs, manufactures, and markets these products globally through its own direct sales channels and various independent distributors. Its product portfolio includes specialized equipment for critical care, obstetrics, and outpatient clinic procedures.
Themes: women's health, neonatal care, obstetrics, medical instrumentation
Fundamentals
- Price$71.55 as of 2026-08-21 close
- Market cap$228M as of 2026-08-21
- 1-year return+24.5% 2025-08-21 close $57.49 → 2026-08-21 close $71.55
- P/E21.02 as of 2026-08-24
- Net margin+28.9% as of 2026-08-24
- Gross margin+57.9% as of 2026-08-24
- ROE+9.1% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)-4.4% as of 2026-08-24
- Revenue CAGR (3y)-9.7% SEC XBRL
- Beta0.40 as of 2026-08-24
- Last reported earnings2026-07-23 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +1.4%; pays a dividend.
How UTMD compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 10% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 10% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- indicated dividend yieldmiddle range 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, UTMD's dividend was covered by reported results (earnings payout 35%, free-cash-flow payout 28%). This describes past coverage, not a forecast.
- Earnings payout35% dividends / net income
- Free-cash-flow payout28% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How UTAH MEDICAL PRODUCTS INC looks technically
UTAH MEDICAL PRODUCTS INC (UTMD) is trading 11.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 139 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 8, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative). It made a new 20-day high about 15 trading days ago. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 3% of the past ~6 months), which often precedes a bigger move. Trading volume is running unusually high — about 3.5× its 30-day average, a sign of heightened interest.
Trend
8
| Distance from the 200-day | it is trading 11.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +11.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $69.75 | $69.75 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $63.93 | $63.93 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 68.15. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 139 trading days ago — a "golden cross", a bullish long-term signal | 139 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 8, below the 25 that marks a real trend) | 8.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30) | 53.4 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($68.15 to $73.50) — its "stochastic" reading is 64 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 63.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative) | 5 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $75.75 | $75.75 |
|---|---|---|
| From the 52-week high | it is 5.5% below its 52-week high (its highest price of the past year) | -5.5% |
| Above the 52-week low | it is 33.3% above its 52-week low (its lowest price of the past year) | +33.3% |
| Below the 52-week high | it is 5.5% below its highest point of the past year | 5.5% |
| Since a 20-day breakout | it made a new 20-day high about 15 trading days ago | 15 sessions |
| Since a 55-day breakout | it made a new 55-day high about 40 trading days ago | 40 sessions |
| All-time high | its highest closing price on record is $133.87 (set on 2021-11-22) | $133.87 |
| Given back of the 52-week move | over the past year its closes ranged ($53.80 to $73.97), and it has given back only a small part of its rise from last year’s low — 12% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $60.86 to $61.50. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 12.0% |
| From the all-time high | it is 46.6% below its all-time high | -46.5% |
| Nearest price level | it is trading 0.9% below a resistance level at $72.17 — a price it turned at twice since 2026-04-17, most recently on 2026-07-16. Since 2024-08-21 it has 10 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.9% |
| All-time low | its lowest closing price on record is $20.04 (set on 2008-12-26) | $20.04 |
| Above the all-time low | it is 257.0% above its all-time low | +257.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 3% of the past ~6 months), which often precedes a bigger move | 3rd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.27 between its high and its low — about 3.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.27 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $69.31 and $73.09 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $69.31 – $71.20 – $73.09 |
| Typical daily range (% of price) | its price moves about 3.2% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.2% |
| Stretch from the 200-day average | it is trading 3.4 daily ranges above its 200-day average price (11.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 3.5× its 30-day average, a sign of heightened interest | 3.52× |
|---|
Candlestick patterns
1
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.5% |
|---|---|---|
| Gap filled | a 2.1% gap up opened on 2026-08-03 has been "filled" 12 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 12 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 1.1 percentage points (the stock gained 3.5% while the market gained 2.3%) | +1.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 7.0 percentage points (the stock gained 10.1% while the market gained 3.1%) | +7.0% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 5.6 percentage points (the stock gained 5.5% while the market gained 11.1%) | -5.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 4.0 percentage points (the stock gained 24.5% while the market gained 20.5%) | +4.0% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 1.7% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 1.7% of the share price, which is taken to mean a barrier that gives way easily. | +1.7% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 6% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $67.21 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +6.5% |
|---|
Price levels it has turned at before
UTMD last closed at $71.55 on 2026-08-21. Since 2024-08-21 it has turned at 10 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $72.17 | Resistance | 0.9% above the last close | turned there twice · 2026-04-17 to 2026-07-16 |
| $68.89 | Support | 3.7% below the last close | turned there three times · 2024-09-19 to 2026-02-20 |
| $75.38 | Resistance | 5.3% above the last close | turned there twice · 2026-06-26 to 2026-08-03 |
| $67.40 | Support | 5.8% below the last close | turned there five times · 2024-09-27 to 2026-08-05 |
| $65.89 | Support | 7.9% below the last close | turned there four times · 2024-09-12 to 2026-07-09 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $68.15.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $79.16 and $85.96 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $68.15.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Unusually heavy trading volume · MACD just crossed bearish (12/26/9) · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · bollinger bands · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Key risks (from latest filing)
["Dependence on regulatory concurrence for new or existing products.","Sensitivity to global economic conditions and foreign currency exchange rate fluctuations.","Competition from larger companies with greater marketing and financial resources."]
What changed in the latest 10-Q
AI-assisted comparison of UTMD's 10-Q filed 2026-05-12 against the prior one filed 2025-11-14.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references Form 10-K for year ended December 31, 2025 (older filing referenced year ended December 31, 2024)
- Newer filing compares 1Q 2026 to 1Q 2025 results; older filing compared 3Q 2025 and 9M 2025 to prior year periods
- Newer filing includes specific narrative about loss of sales to China distributor and PendoTECH customer in 1Q 2026 with combined $857 in 1Q 2025 sales representing 87% of sales decline
- Newer filing discusses constant currency analysis showing additional $169 lower OUS sales due to weaker USD in 1Q 2026
- Newer filing includes statement: 'Historically, sales to UTMD's largest OUS distributor in China had a significantly lower Gross Profit Margin'
- Newer filing specifies one-time yearly adjustment to standard costs which increased inventory value affecting 1Q 2026 gross profit
- Newer filing details specific expense increases: $127 higher litigation expenses, $147 higher employee health care costs, $65 higher OUS operating expenses in 1Q 2026
- Newer filing mentions 96,864 shares repurchased during four calendar quarters following end of 1Q 2025
- Newer filing states cash equivalent balances were $4.1 million higher at March 31, 2026 than March 31, 2025 after using $9.5 million for repurchases, dividends and equipment
- Newer filing reports Stockholders' Equity of $120.4 million at end of 1Q 2026, improved $1.1 million from three months earlier
- Newer filing includes section on Revenues with discussion of T&C of Sale and pricing agreements with clinical facilities
- Removed:
- Older filing's discussion of 3Q 2025 financial performance affected by foreign trade events and cancellation of non-changeable orders by two OUS distributors
- Older filing's narrative about $976 lost shipments, $581 lost revenues, EUR 360 cancellation fee, and $395 bad debt reserve for China distributor
- Older filing's detailed comparison table of WW Operating Expenses excluding litigation and IIA amortization for 3Q and 9M periods
- Older filing's separate tables showing Litigation Expense and UK IIA Amortization Expense for 3Q and 9M comparison periods
- Older filing's statement about September 30, 2025 Balance Sheet being stronger than end of 2024 with higher current ratio and lower total liabilities
- Older filing's reference to 9M 2025 cash payments of $3,006 in dividends and $7,361 for share repurchases
- Older filing's statement that 3Q 2025 ending share price increased $1.50 (+2.4%) from end of 2024
- Reworded:
- Currency notation changed from 'A$ or AUD' in older filing to 'AUD' in newer filing
- Older filing noted Form 10-K covered year ended December 31, 2024; newer filing covers year ended December 31, 2025
- Older filing discussed 'non-prepayment as a practical matter' affecting distributor orders; newer filing uses past tense regarding distributor and OEM customer losses
- Older filing emphasized 'unusually affected by foreign trade events'; newer filing presents distributor/OEM customer losses as expected and previously reported
- Notes:
- Newer filing text appears truncated at the end of revenues section (incomplete sentence about pricing)
- Older filing also appears truncated at the end (incomplete 'Foreign currency exchange (FX) rate' section)
- Comparison involves different reporting periods (1Q 2026 vs. 3Q/9M 2025), making some items non-comparable
Risk Factors
- Added:
- Added Note (2) on Recent Accounting Standards, including ASU 2024-03 (Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures), effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted (filed 2026-05-12)
- Added disclosure that the Company is evaluating the impact of adopting ASU 2024-03 (filed 2026-05-12)
- Added reference to ASU 2025-06 issued in September 2025 regarding Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40), clarifying accounting for internal-use software costs and capitalization thresholds (filed 2026-05-12)
- Removed:
- Removed detailed Risk Factors section that appeared at Item 1A in the older filing (dated 2025-11-14) - the newer filing shows only the heading 'Item 1A. Risk Factors' with page reference but no detailed content in the provided excerpt
- Reworded:
- Accounting standards note structure changed: older filing showed note (1) as sole substantive note; newer filing shows note (1) with similar content plus expanded note (2) on recent accounting standards
- Internal-use software accounting reference added in newer filing: ASU 2025-06 specifies clarifications to Subtopic 350-40 and references to Subtopic 360-10 Property, Plant and Equipment disclosures (filed 2026-05-12)
- Notes:
- The older filing excerpt appears truncated at the notes section; full Risk Factors section content from 2025-11-14 filing is not fully shown, limiting complete comparison of Item 1A Risk Factors
- Financial statements themselves (balance sheets, income statements, cash flows, stockholders' equity) reflect different reporting periods (Q1 2026 vs. Q3 2025) and are not directly comparable changes between filings
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for UTMD — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding UTMD as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 454,227
- Reported value $28,178,176
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 2 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
UTMD had 135,579 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
UTMD had 4.26% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.37 days to cover at the same settlement.
- Reported short interest (shares) 135,579
- Short interest (% of shares outstanding) 4.26%
- Prior settlement (shares) 140,086
- Reported change -3.22%
- Days to cover (reported) 3.37
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- CooperSurgical (COO)
- Becton, Dickinson and Company (BDX)
- Cardinal Health (CAH)
- Medtronic (MDT)
- Teleflex (TFX)
- ICU Medical (ICUI)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare UTMD vs…
Frequently asked questions
What does UTAH MEDICAL PRODUCTS INC (UTMD) do?
Utah Medical Products produces medical devices focused on neonatal intensive care, labor and delivery, and women's health. The company designs, manufactures, and markets these products globally through its own direct sales channels and various independent distributors. Its product portfolio includes specialized equipment for critical care, obstetrics, and outpatient clinic procedures.
What sector is UTAH MEDICAL PRODUCTS INC (UTMD) in?
UTAH MEDICAL PRODUCTS INC (UTMD) is classified in the Health Care sector. Its industry is Medical Devices. It trades on NASDAQ.
Does UTMD pay a dividend?
Yes — UTAH MEDICAL PRODUCTS INC (UTMD) pays a dividend, with an indicated yield of about 1.45% (market data, as of 2026-08-24). Informational only — not financial advice.
Who are UTAH MEDICAL PRODUCTS INC's (UTMD) competitors?
Notable peers of UTAH MEDICAL PRODUCTS INC (UTMD) include CooperSurgical, Becton, Dickinson and Company, Cardinal Health, Medtronic and Teleflex. This peer set is informational only — not financial advice.
Is UTAH MEDICAL PRODUCTS INC (UTMD) overbought or oversold right now?
UTAH MEDICAL PRODUCTS INC (UTMD) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 53, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on UTMD come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.